<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00638898</url>
  </required_header>
  <id_info>
    <org_study_id>03112</org_study_id>
    <secondary_id>NCI-2009-01600</secondary_id>
    <nct_id>NCT00638898</nct_id>
  </id_info>
  <brief_title>Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor</brief_title>
  <official_title>Pilot Study of High-Dose Chemotherapy With Busulfan, Melphalan, and Topotecan Followed by Autologous Hematopoietic Stem Cell Transplant in Advanced Stage and Recurrent Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>City of Hope Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>City of Hope Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Giving high-dose chemotherapy before an autologous stem cell transplant stops the&#xD;
      growth of tumor cells by stopping them from dividing or killing them. Giving&#xD;
      colony-stimulating factors, such as G-CSF, helps stem cells move from the bone marrow to the&#xD;
      blood so they can be collected and stored. Chemotherapy is then given to prepare the bone&#xD;
      marrow for the stem cell transplant. The stem cells are then returned to the patient to&#xD;
      replace the blood-forming cells that were destroyed by the chemotherapy.&#xD;
&#xD;
      PURPOSE: This clinical trial is studying how well giving busulfan, melphalan, and topotecan&#xD;
      hydrochloride together with a stem cell transplant works in treating patients with newly&#xD;
      diagnosed or relapsed solid tumor.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. To assess the feasibility of a novel combination conditioning therapy with&#xD;
      busulfan/melphalan and topotecan followed by autologous hematopoietic stem cell&#xD;
      transplantation (HSCT) in patients with relapsed, refractory and/or poor risk pediatric solid&#xD;
      tumors.&#xD;
&#xD;
      II. To determine within the confines of this pilot study, myeloid and platelet engraftment,&#xD;
      overall survival and disease-free survival in patients with relapsed, refractory pediatric&#xD;
      solid tumors and in patients who have solid tumors with poor risk factors at the time of&#xD;
      diagnosis.&#xD;
&#xD;
      III. To determine the pharmacokinetics of topotecan.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      AUTOLOGOUS HEMATOPOIETIC STEM CELL OR AUTOLOGOUS BONE MARROW COLLECTION: Patients undergo&#xD;
      stem cell mobilization per institutional guidelines with G-CSF IV or subcutaneously,&#xD;
      continuing until the completion of leukapheresis. Patients undergo apheresis after&#xD;
      mobilization and continue until a minimum of 2.0 x 10^6 CD34 cells/kg or more are collected.&#xD;
      Cells are processed and cryopreserved following institutional guidelines. Patients who&#xD;
      collect &gt; 2.0 x 10^6 CD34+ cells/kg may proceed to high-dose chemotherapy.&#xD;
&#xD;
      HIGH-DOSE CHEMOTHERAPY: Patients receive topotecan hydrochloride IV continuously over 24&#xD;
      hours on days -8 to -4, busulfan IV every 6 hours on days -8 to -4, and melphalan IV over 30&#xD;
      minutes on days -3 and -2.&#xD;
&#xD;
      AUTOLOGOUS HEMATOPOIETIC STEM CELL OR AUTOLOGOUS BONE MARROW REINFUSION: Patients undergo&#xD;
      autologous hematopoietic stem cell transplantation or autologous bone marrow transplantation&#xD;
      on day 0. Patients also receive G-CSF IV daily beginning on day +5 and continuing until blood&#xD;
      counts recover.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 3 months for 1 year and then&#xD;
      annually thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 26, 2007</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment feasibility in terms of investigational agent-related adverse events of a novel treatment combination followed by peripheral blood stem cell rescue</measure>
    <time_frame>Day 100 post stem cell rescue</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1 year post stem cell rescue</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>1 year post stem cell rescue</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of myeloid and platelet engraftment</measure>
    <time_frame>Day 100 post stem cell rescue</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics and pharmacodynamics of topotecan hydrochloride and busulfan</measure>
    <time_frame>Baseline through day 4 of investigational agent treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Solid Tumor</condition>
  <condition>Adult Central Nervous System Germ Cell Tumor</condition>
  <condition>Adult Rhabdomyosarcoma</condition>
  <condition>Childhood Central Nervous System Germ Cell Tumor</condition>
  <condition>Childhood Soft Tissue Sarcoma</condition>
  <condition>Ewing Sarcoma</condition>
  <condition>Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor</condition>
  <condition>Ovarian Mixed Germ Cell Tumor</condition>
  <condition>Previously Untreated Childhood Rhabdomyosarcoma</condition>
  <condition>Recurrent Adult Brain Tumor</condition>
  <condition>Recurrent Adult Soft Tissue Sarcoma</condition>
  <condition>Recurrent Childhood Brain Stem Glioma</condition>
  <condition>Recurrent Childhood Cerebellar Astrocytoma</condition>
  <condition>Recurrent Childhood Cerebral Astrocytoma</condition>
  <condition>Recurrent Childhood Ependymoma</condition>
  <condition>Recurrent Childhood Malignant Germ Cell Tumor</condition>
  <condition>Recurrent Childhood Medulloblastoma</condition>
  <condition>Recurrent Childhood Pineoblastoma</condition>
  <condition>Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor</condition>
  <condition>Recurrent Childhood Visual Pathway and Hypothalamic Glioma</condition>
  <condition>Recurrent Childhood Visual Pathway Glioma</condition>
  <condition>Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor</condition>
  <condition>Recurrent Extragonadal Germ Cell Tumor</condition>
  <condition>Recurrent Extragonadal Non-seminomatous Germ Cell Tumor</condition>
  <condition>Recurrent Malignant Testicular Germ Cell Tumor</condition>
  <condition>Recurrent Neuroblastoma</condition>
  <condition>Recurrent Ovarian Germ Cell Tumor</condition>
  <condition>Recurrent Wilms Tumor and Other Childhood Kidney Tumors</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <condition>Unspecified Childhood Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See Detailed Description</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>BSF</other_name>
    <other_name>BU</other_name>
    <other_name>Misulfan</other_name>
    <other_name>Mitosan</other_name>
    <other_name>Myeloleukon</other_name>
    <other_name>Myelosan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>Alkeran</other_name>
    <other_name>CB-3025</other_name>
    <other_name>L-PAM</other_name>
    <other_name>L-phenylalanine mustard</other_name>
    <other_name>L-Sarcolysin</other_name>
    <other_name>Melfalan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>topotecan hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>hycamptamine</other_name>
    <other_name>Hycamtin</other_name>
    <other_name>SKF S-104864-A</other_name>
    <other_name>TOPO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <description>Given IV or subcutaneously</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>G-CSF</other_name>
    <other_name>granulocyte colony-stimulating factor</other_name>
    <other_name>Neupogen</other_name>
    <other_name>r-metHuG-CSF</other_name>
    <other_name>Recombinant Methionyl Human Granulocyte Colony Stimulating Factor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>autologous hematopoietic stem cell transplantation</intervention_name>
    <description>Undergo transplantation</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>autologous bone marrow transplantation</intervention_name>
    <description>Undergo transplantation</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>ABMT</other_name>
    <other_name>bone marrow transplantation, autologous</other_name>
    <other_name>transplantation, autologous bone marrow</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion&#xD;
&#xD;
          -  Patients with relapsed neuroblastoma, rhabdomyosarcoma, Ewing's sarcoma, PNET, brain&#xD;
             tumors, soft tissue sarcomas, Wilm's tumors, germ cell tumors or other solid tumors&#xD;
             who achieved at least partial response (PR) to chemotherapy, surgery, or radiotherapy&#xD;
&#xD;
          -  Newly diagnosed patients for poor-risk pediatric solid tumors: metastatic Ewing's,&#xD;
             metastatic PNET, rhabdomyosarcoma, soft tissue sarcomas, octeomesenchymoma, and others&#xD;
             that are at a high risk of relapse and who have achieved at least partial response&#xD;
             (PR) to chemotherapy, surgery, or radiotherapy&#xD;
&#xD;
          -  For any of the above categories, an attempt to achieve a complete response (CR) or PR&#xD;
             should be made; pre-transplant modalities may include surgery, chemotherapy, or&#xD;
             radiation therapy; radiation must not include lung fields; only patients in CR or PR&#xD;
             at the primary site will be eligible&#xD;
&#xD;
          -  HIGH-DOSE CHEMOTHERAPY: Histologically confirmed diagnosis by Anatomic Pathology&#xD;
             Department; if recurrent or metastatic disease, histologic confirmation should be&#xD;
             obtained, with the exception of brain stem tumors; in neuroblastoma, demonstration of&#xD;
             marrow metastases with elevated urinary catecholamines is adequate for diagnosis&#xD;
&#xD;
          -  HIGH-DOSE CHEMOTHERAPY: No contraindications to the stem cell collection by apheresis&#xD;
             or by bone marrow harvesting&#xD;
&#xD;
          -  HIGH-DOSE CHEMOTHERAPY: All patients, or their legal guardians must have signed a&#xD;
             voluntary informed consent in accordance with the institutional and federal guidelines&#xD;
&#xD;
          -  HIGH-DOSE CHEMOTHERAPY: Adequate renal function as demonstrated by creatinine&#xD;
             clearance (12 or 24 hour urine collection) or glomerular filtration rate (GFR) &gt; 60&#xD;
             ml/min/1.73m^2&#xD;
&#xD;
          -  HIGH-DOSE CHEMOTHERAPY: Adequate cardiac function as demonstrated by ejection fraction&#xD;
             &gt; 55% by echocardiogram or MUGA&#xD;
&#xD;
          -  HIGH-DOSE CHEMOTHERAPY: Adequate hepatic function as demonstrated by bilirubin &lt; 2&#xD;
             mg/dL, SGOT and SGPT &lt; 5 x upper limits of normal&#xD;
&#xD;
          -  HIGH-DOSE CHEMOTHERAPY: Adequate bone marrow function as evidenced by platelet count &gt;&#xD;
             50,000/ul and absolute granulocyte count &gt;= 750 ul&#xD;
&#xD;
          -  HIGH-DOSE CHEMOTHERAPY: Adequate pulmonary function adults (older than 16 years): FEV1&#xD;
             &gt; 2 liters, room air PaO2 &gt; 70 mm Hg, room air PaCO2 &lt; 42 mm Hg, and DLCO &gt; 50%&#xD;
             predicted; children (younger than 16 years): DLCO &gt; 50% predicted&#xD;
&#xD;
          -  HIGH-DOSE CHEMOTHERAPY: Pretreatment tests and clinical and laboratory tests must have&#xD;
             been performed within 4 weeks prior to initiation of high-dose chemotherapy&#xD;
&#xD;
          -  HIGH-DOSE CHEMOTHERAPY: No other medical and/or psychosocial problems which in the&#xD;
             opinion of the primary physician or principal investigator would place the patient at&#xD;
             unacceptable risk from this regimen&#xD;
&#xD;
          -  HIGH-DOSE CHEMOTHERAPY: Greater than 2-week period of recovery from prior modality&#xD;
             used to control primary or recurrent site&#xD;
&#xD;
        Exclusion&#xD;
&#xD;
          -  Histologically confirmed bone marrow metastases within 30 days prior to transplant;&#xD;
             prior bone marrow metastases with clearing of bone marrow (&lt; 5% contamination as&#xD;
             measured by bilateral bone marrow biopsies) at the time for evaluation for this&#xD;
             protocol is acceptable&#xD;
&#xD;
          -  Karnofsky performance status &lt; 60% or Lansky performance status &lt; 50% for patients&#xD;
             younger than 16 years old&#xD;
&#xD;
          -  Females of reproductive age who are not using adequate birth control measures or who&#xD;
             are pregnant&#xD;
&#xD;
          -  HIV disease&#xD;
&#xD;
          -  Patients with prior treatment with myeloablative therapy are excluded&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anna Pawlowska, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>City of Hope Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>March 18, 2008</study_first_submitted>
  <study_first_submitted_qc>March 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2008</study_first_posted>
  <last_update_submitted>February 15, 2021</last_update_submitted>
  <last_update_submitted_qc>February 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Neuroblastoma</mesh_term>
    <mesh_term>Neoplasms, Germ Cell and Embryonal</mesh_term>
    <mesh_term>Astrocytoma</mesh_term>
    <mesh_term>Rhabdomyosarcoma</mesh_term>
    <mesh_term>Ependymoma</mesh_term>
    <mesh_term>Sarcoma, Ewing</mesh_term>
    <mesh_term>Medulloblastoma</mesh_term>
    <mesh_term>Neuroectodermal Tumors</mesh_term>
    <mesh_term>Neuroectodermal Tumors, Primitive</mesh_term>
    <mesh_term>Wilms Tumor</mesh_term>
    <mesh_term>Testicular Neoplasms</mesh_term>
    <mesh_term>Neuroectodermal Tumors, Primitive, Peripheral</mesh_term>
    <mesh_term>Pinealoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Topotecan</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

